Automated manufacturing of CAR NK cells

Live webinar

This webinar will review the current status of CAR NK cell-based immunotherapy. Martha Elia Luevano Salinas, global product manager of NK cells at Miltenyi Biotec, will discuss the following topics:

  • Strategies used to generate CAR NK cells for immunotherapy
  • Current approaches to increase CAR NK cell cytotoxicity
  • Introduction to the new CliniMACS Prodigy Platform, a unique platform that allows generation of gene-modified CAR NK cells in a standardized and fully automated fashion

There will be time for questions and discussion after the 45-minute webinar


Sessions (choice of two dates)

September 10, 2019
Berlin, Germany (GMT+02:00) – 7:00 PM CET
New York, NY, USA (GMT-04:00) – 1:00 PM EDT
San Francisco, CA, USA (GMT-07:00) – 10:00 AM PST

Register here

September 12, 2019
Berlin, Germany (GMT+02:00) – 10:00 AM CET
London, United Kingdom (GMT+01:00) –  9:00 AM GMT
Singapore, Singapore (GMT+08:00) – 4:00 PM 

Register here


About the presenter

Martha completed her postdoctoral research in stem cells (Miltenyi Biotec-Marie Curie fellowship) and her Ph.D. at the Anthony Nolan Institute (University College London), finding solutions to expand NK cells for therapeutic purposes. Her combined experience in molecular and cellular research has made her the recipient of international grants and fellowships.

Martha Elia Luevano Salinas, Ph.D., Miltenyi Biotec